Related Experiment Video
Updated: Mar 28, 2026
09:29
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
31.0K
Update on hepatitis C: Direct-acting antivirals.
Leon L Seifert1, Ryan B Perumpail1, Aijaz Ahmed1
1Leon L Seifert, Department of Transplantation Medicine, University Hospital Münster, 48149 Münster, Germany.
World Journal of Hepatology
|December 16, 2015
Summary
Direct-acting antivirals (DAAs) have transformed Hepatitis C virus (HCV) treatment, offering highly effective, well-tolerated oral regimens. Real-world data confirm DAA efficacy, bringing HCV eradication closer to reality.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection has been a significant global health concern for decades.
- Interferon-based therapies were the standard treatment but had limitations.
- The recent advent of direct-acting antivirals (DAAs) marks a paradigm shift in HCV management.
Purpose of the Study:
- To review the impact of direct-acting antivirals (DAAs) on Hepatitis C virus (HCV) treatment.
- To highlight the efficacy and tolerability of new DAA regimens.
- To assess the potential for HCV eradication with current treatment strategies.
Main Methods:
- Review of recent clinical trials and emerging real-world data on DAAs.
- Analysis of treatment outcomes, including sustained virological response (SVR) rates.
- Comparison of DAA regimens with historical interferon-based therapies.
Main Results:
- DAAs have led to all-oral treatment regimens for HCV.
- These regimens demonstrate favorable side effect profiles.
- High rates of sustained virological response are achieved with DAAs, comparable to clinical trial data in real-world settings.
Conclusions:
- Direct-acting antivirals have revolutionized HCV treatment.
- The efficacy and tolerability of DAAs offer a promising path towards HCV eradication.
- Real-world evidence supports the widespread use of DAAs for combating HCV.
Related Concept Videos
01:25Hepatitis
34
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
01:30Inhibitors of Viral Protein Synthesis
20
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
20
01:10Retrovirus Life Cycles
50.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:29Subviral Agents
745
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
745
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K